1. Evaluation of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) Samples from Advanced Non-Small Cell Lung Cancer for Whole Genome, Whole Exome and Comprehensive Panel Sequencing.
- Author
-
Fielding, David, Lakis, Vanessa, Dalley, Andrew J., Chittoory, Haarika, Newell, Felicity, Koufariotis, Lambros T., Patch, Ann-Marie, Kazakoff, Stephen, Bashirzadeh, Farzad, Son, Jung Hwa, Ryan, Kimberley, Steinfort, Daniel, Williamson, Jonathan P., Bint, Michael, Pahoff, Carl, Nguyen, Phan Tien, Twaddell, Scott, Arnold, David, Grainge, Christopher, and Pattison, Andrew
- Subjects
- *
LUNG cancer , *BIOMARKERS , *ULTRASONIC imaging , *SEQUENCE analysis , *GENETIC mutation , *PATHOGENESIS , *GENOMES , *RESEARCH funding , *NEEDLE biopsy , *NUCLEIC acids - Abstract
Simple Summary: EBUS-TBNA specimens are the most common source of diagnostic tissue from patients with advanced inoperable lung cancer. Genomic testing is critical to inform treatment options, and a wider adoption of comprehensive sequencing would improve the detection of actionable mutations and outcomes for patients. However, patients can miss out on genomic testing when there is insufficient sample in the EBUS-TBNA specimen. Here we evaluated the largest cohort of freshly collected EBUS-TBNA specimens and compared across three comprehensive sequencing platforms for the detection of actionable mutations and potential biomarkers of treatment responses. This study demonstrates the enormous potential of fresh EBUS-TBNA samples as important biospecimens for clinical testing and for treatment response biomarker discovery. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is often the only source of tumor tissue from patients with advanced, inoperable lung cancer. EBUS-TBNA aspirates are used for the diagnosis, staging, and genomic testing to inform therapy options. Here we extracted DNA and RNA from 220 EBUS-TBNA aspirates to evaluate their suitability for whole genome (WGS), whole exome (WES), and comprehensive panel sequencing. For a subset of 40 cases, the same nucleic acid extraction was sequenced using WGS, WES, and the TruSight Oncology 500 assay. Genomic features were compared between sequencing platforms and compared with those reported by clinical testing. A total of 204 aspirates (92.7%) had sufficient DNA (100 ng) for comprehensive panel sequencing, and 109 aspirates (49.5%) had sufficient material for WGS. Comprehensive sequencing platforms detected all seven clinically reported tier 1 actionable mutations, an additional three (7%) tier 1 mutations, six (15%) tier 2–3 mutations, and biomarkers of potential immunotherapy benefit (tumor mutation burden and microsatellite instability). As expected, WGS was more suited for the detection and discovery of emerging novel biomarkers of treatment response. WGS could be performed in half of all EBUS-TBNA aspirates, which points to the enormous potential of EBUS-TBNA as source material for large, well-curated discovery-based studies for novel and more effective predictors of treatment response. Comprehensive panel sequencing is possible in the vast majority of fresh EBUS-TBNA aspirates and enhances the detection of actionable mutations over current clinical testing. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF